Skip to main content

Simon Heller

Simon Heller is Professor of Clinical Diabetes at the University of Sheffield, Director of Research and Development and Honorary Consultant Physician at Sheffield Teaching Hospitals Foundation Trust, UK. He is currently a member of Diabetes UK Science and Research Advisory Group, a member of the UK NIHR Programme Grants for Applied Research Panel and the UK Juvenile Diabetes Research Foundation, UK Scientific Advisory Committee. He was Editor in Chief of Diabetic Medicine from 2000-2005. He is currently the National Speciality Lead in Diabetes to the UK NIHR Clinical Research Network. He is an NIHR Senior Investigator. His current research interests include the pathophysiological responses to hypoglycaemia and hypoglycaemia unawareness, the potential contribution and mechanisms of hypoglycaemia to cardiovascular mortality, the use of insulin analogues and other technologies to reduce hypoglycaemia. He chaired the glucose control group of the ADVANCE trial and was the PI on the REPOSE trial measuring the effectiveness of insulin pumps. He also conducts research programmes concerned with developing interventions (including the DAFNE intervention) to encourage more effective diabetes self-management. He chairs the International Hypoglycaemia Study Group, 15 professionals and academics with expertise in diabetic hypoglycaemia who have recently been working with both ADA and EASD to extend the classification of hypoglycaemia

print
PRINT

Latest contributions from Simon Heller

Simon Heller and Shehla Shaikh

04-11-2022 | Type 1 diabetes | Ask the expert | Article

Ramadan and type 1 diabetes: Supporting religious fasting

Simon Heller from the UK talks to Shehla Shaikh from India to learn from her wealth of experience in supporting people with type 1 diabetes to fast during Ramadan.

Doctor testing a person's blood glucose

11-05-2021 | Hypoglycemia | News

Repeated nonsevere hypoglycemia warrants attention in type 2 diabetes

A high rate of nonsevere hypoglycemic episodes is associated with risk for severe hypoglycemia, major adverse cardiovascular events, and mortality in people with type 2 diabetes, shows an analysis of LEADER data.

CGM_action

10-16-2019 | Continuous glucose monitoring | Feature | Article

CGM time in range: A higher standard for an engaged few?

Simon Heller explains why time-in-range targets are so helpful for people with diabetes… yet handing out continuous glucose monitoring devices willy-nilly could do more harm than good.

06-24-2018 | Insulin degludec | ADA 2018 | News

Degludec benefits consistent in elderly patients

Degludec delivers the same magnitude of protection against hypoglycemia relative to glargine across patient age groups, shows analysis of the SWITCH 2 and DEVOTE trials.

Insulin pump

03-31-2017 | Glycemic control | News

Insulin pumps do not boost education effects on glycemic control

Research shows that switching to an insulin pump does not improve glycemic control in patients referred to an educational program after struggling to control their type 1 diabetes with multiple daily injections.